Table 4 Comparison between WT1 genotyping and AML patients’ data
Parameters | Variables | WT1 (N = 63) | P value | |
|---|---|---|---|---|
GG + AG (mutant) (N = 17) | AA (wild) (N = 46) | |||
Gender | Male | 8 (47.1%) | 28 (60.9%) | 0.395 |
Female | 9 (52.9%) | 18 (39.1%) | ||
Liver | Normal | 12 (70.6%) | 32 (69.6%) | 0.937 |
Enlarged | 5 (29.4%) | 14 (30.4%) | ||
Spleen | Normal | 10 (58.8%) | 30 (62.2%) | 0.770 |
Enlarged | 7 (41.2%) | 16 (34.8%) | ||
Lymph node | Normal | 9 (52.9%) | 35 (70.1%) | 0.076 |
Enlarged | 8 (47.1%) | 11 (23.9%) | ||
Response (28 days) | Died | 0 (0%) | 17 (36.9%) | 0.001 |
CR | 17 (100%) | 3 (6.4%) | ||
PR | 0 (0%) | 26 (56.5%) | ||
Response (6 months) | Died | 1 (5.9%) | 25 (54.3%) | 0.001 |
CR | 15 (88.2%) | 11 (23.4%) | ||
Relapse | 1 (5.8%) | 10 (21.7%) | ||
Response (24 months) | Died or relapse | 2 (11.8%) | 36 (78.3%) | 0.001 |
CR | 15 (88.2%) | 10 (21.3%) | ||
AML subtype | M0 | 2 (11.8%) | 2 (4.3%) | 0.139 |
M1 | 5 (29.4%) | 9 (19.6%) | ||
M2 | 8 (40.1%) | 19 (41.3%) | ||
M4 | 0 (0%) | 3 (65.2%) | ||
M5 | 1 (5.9%) | 13 (28.3%) | ||
M7 | 1 (5.9%) | 0 (0%) | ||
Immunophenotyping | CD33- | 3 (17.6%) | 2 (4.3%) | 0.117 |
CD33+ | 14 (82.4%) | 44 (95,6%) | ||
CD13- | 2 (11.8%) | 7 (15.2%) | 0.542 | |
CD13+ | 15 (88.2%) | 39 (84.8%) | ||
CD14- | 15 (88.2%) | 41 (89.1%) | 0.615 | |
CD14+ | 2 (11.8%) | 5 (10.9%) | ||
CD117- | 2 (11.8%) | 17 (36.2%) | 0.047 | |
CD117+ | 15 (88.2%) | 29 (61.7%) | ||
MPO- | 5 (39.4%) | 5 (10.9%) | 0.085 | |
MPO+ | 12 (60.6%) | 41 (89.1%) | ||
CD34- | 6 (35.3%) | 20 (34.5%) | 0.386 | |
CD34+ | 11 (64.7%) | 26 (56.5%) | ||